Table 2 Effect of treatment with MMINA on antioxidant parameters in cisplatin-treated rat organs.

From: Molecular docking, pharmacokinetic studies, and in vivo pharmacological study of indole derivative 2-(5-methoxy-2-methyl-1H-indole-3-yl)-N′-[(E)-(3-nitrophenyl) methylidene] acetohydrazide as a promising chemoprotective agent against cisplatin induced organ damage

Treatments

SOD (U/g)

GPx (nM/min/g)

Liver

Kidney

Heart

Brain

Liver

Kidney

Heart

Brain

Control

35.91 ± 0.47

46.67 ± 1.17

33.94 ± 0.94

29.96 ± 0.52

45.68 ± 1.09

55.25 ± 0.87

39.63 ± 0.92

41.52 ± 0.63

DMSO Vehicle

35.83 ± 0.81

46.35 ± 1.01

33.78 ± 0.96

30.04 ± 0.60

45.43 ± 0.99

54.97 ± 0.74

39.49 ± 0.63

41.24 ± 0.70

Cisplatin (12.5 mg/kg)

7.3 ± 0.65****

5.06 ± 0.46****

6.07 ± 0.61****

4.24 ± 0.03****

9.14 ± 0.25****

7.45 ± 0.54****

6.79 ± 0.79****

6.07 ± 0.60****

Cisplatin + MMINA

30.39 ± 0.97++++

39.87 ± 1.03++++

28.31 ± 0.77++++

23. 20 ± 0.57++++

39.32 ± 0.31++++

47.07 ± 0.55++++

31.27 ± 0.92++++

38.04 ± 0.65++++

MMINA (25 mg/kg)

38.66 ± 0.52++++

47.89 ± 1.13++++

34.60 ± 0.90++++

32.11 ± 0.96++++

46.01 ± 0.85++++

56.35 ± 0.67++++

41.17 ± 0.92++++

42.14 ± 0.81++++

  1. Data are mean ± SEM, (n = 6). *, ****p < 0.05 and p < 0.0001 versus Control respectively, and ++++p < 0.0001 versus CP. Data analyzed by One-way ANOVA followed by Tukey’s multiple comparison tests.
Back to article page